Pegfilgrastim (P) administration after 24, 72, or 96 hours (h) to allow dose-dense (DD) anthracycline- and taxane-based chemotherapy (CT) in breast cancer (BC) patients (pts): A single-center experience within the GIM2 randomized phase III study.
Matteo Lambertini
No relevant relationships to disclose
Matteo Clavarezza
No relevant relationships to disclose
Francesca Poggio
No relevant relationships to disclose
Simona Pastorino
No relevant relationships to disclose
Annalisa Abate
No relevant relationships to disclose
Claudia Bighin
No relevant relationships to disclose
Paolo Pronzato
No relevant relationships to disclose
Lucia Del Mastro
No relevant relationships to disclose